Godavari Drugs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 11, 2025, 12:16 am

Market Cap	60.8 Cr.
Current Price	80.7
High / Low	134/78.9
Stock P/E	16.0
Book Value	57.6
Dividend Yield	0.00 %
ROCE	10.1 %
ROE	10.6 %
Face Value	10.0
PEG Ratio	-2.53

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Godavari Drugs Ltd

Competitors of Godavari Drugs Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	136 Cr.	108	247/84.3	31.0	46.7	0.00 %	12.9 %	9.69 %	10.0
MPS Pharmaa Ltd	3.52 Cr.	1.84	4.33/1.82		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	4,937 Cr.	453	479/192	102	24.3	0.15 %	27.3 %	21.7 %	1.00
Gujarat Terce Laboratories Ltd	33.4 Cr.	45.1	92.2/37.2		10.6	0.00 %	41.4 %	14.6 %	10.0
Gujarat Inject (Kerala) Ltd	37.3 Cr.	25.4	29.1/17.0	38.8	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	19,998.92 Cr	1,191.15		55.95	199.13	0.34%	16.24%	14.95%	6.10

All Competitor Stocks of Godavari Drugs Ltd

Quarterly Result

Metric	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	42.55	40.55	39.16	37.37	35.42	39.54	43.11	38.64	32.21	26.09	29.55	25.50	23.81
Expenses	40.15	37.98	36.89	34.69	33.17	36.47	39.59	34.17	28.98	23.19	26.97	22.39	20.91
Operating Profit	2.40	2.57	2.27	2.68	2.25	3.07	3.52	4.47	3.23	2.90	2.58	3.11	2.90
OPM %	5.64%	6.34%	5.80%	7.17%	6.35%	7.76%	8.17%	11.57%	10.03%	11.12%	8.73%	12.20%	12.18%
Other Income	0.07	0.13	0.30	0.39	0.45	0.00	-0.01	0.08	0.77	0.01	0.10	0.11	0.01
Interest	0.74	1.06	1.10	1.03	1.11	1.30	1.27	1.23	1.44	1.08	1.11	1.11	1.00
Depreciation	0.46	0.47	0.51	0.50	0.47	0.49	0.50	0.53	0.55	0.58	0.64	0.67	0.60
Profit before tax	1.27	1.17	0.96	1.54	1.12	1.28	1.74	2.79	2.01	1.25	0.93	1.44	1.31
Tax %	26.77%	26.50%	30.21%	13.64%	27.68%	32.81%	29.89%	4.66%	18.91%	12.80%	16.13%	38.19%	19.85%
Net Profit	0.92	0.86	0.67	1.33	0.81	0.86	1.22	2.66	1.63	1.09	0.77	0.89	1.04
EPS in Rs	1.22	1.14	0.89	1.77	1.08	1.14	1.62	3.53	2.16	1.45	1.02	1.18	1.38

Last Updated: August 19, 2025, 2:35 pm

Below is a detailed analysis of the quarterly data for Godavari Drugs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

For Sales, as of Jun 2025, the value is 23.81 Cr.. The value appears to be declining and may need further review. It has decreased from 25.50 Cr. (Mar 2025) to 23.81 Cr., marking a decrease of 1.69 Cr..
For Expenses, as of Jun 2025, the value is 20.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.39 Cr. (Mar 2025) to 20.91 Cr., marking a decrease of 1.48 Cr..
For Operating Profit, as of Jun 2025, the value is 2.90 Cr.. The value appears to be declining and may need further review. It has decreased from 3.11 Cr. (Mar 2025) to 2.90 Cr., marking a decrease of 0.21 Cr..
For OPM %, as of Jun 2025, the value is 12.18%. The value appears to be declining and may need further review. It has decreased from 12.20% (Mar 2025) to 12.18%, marking a decrease of 0.02%.
For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.11 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 0.11 Cr..
For Depreciation, as of Jun 2025, the value is 0.60 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.67 Cr. (Mar 2025) to 0.60 Cr., marking a decrease of 0.07 Cr..
For Profit before tax, as of Jun 2025, the value is 1.31 Cr.. The value appears to be declining and may need further review. It has decreased from 1.44 Cr. (Mar 2025) to 1.31 Cr., marking a decrease of 0.13 Cr..
For Tax %, as of Jun 2025, the value is 19.85%. The value appears to be improving (decreasing) as expected. It has decreased from 38.19% (Mar 2025) to 19.85%, marking a decrease of 18.34%.
For Net Profit, as of Jun 2025, the value is 1.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.89 Cr. (Mar 2025) to 1.04 Cr., marking an increase of 0.15 Cr..
For EPS in Rs, as of Jun 2025, the value is 1.38. The value appears strong and on an upward trend. It has increased from 1.18 (Mar 2025) to 1.38, marking an increase of 0.20.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 1:02 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	9	55	71	76	64	84	96	123	161	160	157	113	105
Expenses	8	49	67	70	60	78	90	113	150	150	143	102	93
Operating Profit	2	6	4	5	4	5	6	10	11	10	13	12	11
OPM %	20%	11%	6%	7%	6%	7%	6%	8%	7%	6%	8%	10%	11%
Other Income	0	0	0	1	1	0	0	0	0	1	1	1	0
Interest	0	1	2	3	2	3	3	3	3	4	5	5	4
Depreciation	1	1	1	1	1	1	1	1	2	2	2	2	2
Profit before tax	1	5	2	3	1	2	2	6	7	5	7	6	5
Tax %	-121%	23%	38%	33%	37%	31%	13%	28%	25%	23%	20%	22%
Net Profit	2	4	1	2	1	1	2	4	5	4	6	4	4
EPS in Rs	2.06	4.85	1.79	2.40	1.10	1.61	2.66	5.48	6.97	5.03	7.37	5.82	5.03
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	100.00%	-75.00%	100.00%	-50.00%	0.00%	100.00%	100.00%	25.00%	-20.00%	50.00%	-33.33%
Change in YoY Net Profit Growth (%)	0.00%	-175.00%	175.00%	-150.00%	50.00%	100.00%	0.00%	-75.00%	-45.00%	70.00%	-83.33%

Godavari Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	8%
5 Years:	3%
3 Years:	-11%
TTM:	-32%

Compounded Profit Growth
10 Years:	2%
5 Years:	17%
3 Years:	-6%
TTM:	-41%

Stock Price CAGR
10 Years:	4%
5 Years:	17%
3 Years:	7%
1 Year:	-41%

Return on Equity
10 Years:	13%
5 Years:	15%
3 Years:	13%
Last Year:	11%

Last Updated: September 5, 2025, 3:36 pm

No data available for the Balance Sheet data table.

Reserves and Borrowings Chart

Cash Flow - No data available for this post.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	20	87	126	117	152	148	137	134	126	132	138	136
Inventory Days	973	84	67	70	100	93	84	55	28	57	62	125
Days Payable	179	79	108	124	171	171	144	112	121	132	96	128
Cash Conversion Cycle	814	92	85	63	81	70	78	78	33	58	105	133
Working Capital Days	120	63	44	40	47	38	31	46	32	23	9	11
ROCE %	8%	32%	16%	17%	11%	12%	12%	18%	18%	14%	14%	10%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	53.12%	53.12%	53.16%	53.16%	53.16%	53.16%	53.16%	52.63%	52.63%	52.63%	52.63%	52.61%
DIIs	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%
Public	46.37%	46.39%	46.34%	46.33%	46.35%	46.34%	46.34%	46.87%	46.87%	46.87%	46.87%	46.90%
No. of Shareholders	6,651	6,555	6,561	7,019	6,894	7,005	7,044	7,709	7,915	7,881	7,828	7,720

Shareholding Pattern Chart

No. of Shareholders

Godavari Drugs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE / ROE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	5.82	7.37	5.03	6.97	5.48
Diluted EPS (Rs.)	5.82	7.37	5.03	6.97	5.48
Cash EPS (Rs.)	9.07	10.02	7.61	9.22	7.11
Book Value[Excl.RevalReserv]/Share (Rs.)	57.56	51.74	44.38	39.35	32.38
Book Value[Incl.RevalReserv]/Share (Rs.)	57.56	51.74	44.38	39.35	32.38
Revenue From Operations / Share (Rs.)	150.52	208.10	211.97	213.94	162.90
PBDIT / Share (Rs.)	17.00	18.49	14.04	15.36	13.59
PBIT / Share (Rs.)	13.75	15.84	11.46	13.11	11.97
PBT / Share (Rs.)	7.47	9.19	6.55	9.32	7.58
Net Profit / Share (Rs.)	5.82	7.37	5.03	6.96	5.48
PBDIT Margin (%)	11.29	8.88	6.62	7.17	8.34
PBIT Margin (%)	9.13	7.61	5.40	6.12	7.34
PBT Margin (%)	4.96	4.41	3.09	4.35	4.65
Net Profit Margin (%)	3.86	3.54	2.37	3.25	3.36
Return on Networth / Equity (%)	10.10	14.24	11.32	17.70	16.92
Return on Capital Employeed (%)	14.79	22.60	18.08	22.61	22.18
Return On Assets (%)	3.06	4.11	3.11	5.17	4.52
Long Term Debt / Equity (X)	0.55	0.28	0.35	0.39	0.59
Total Debt / Equity (X)	1.42	1.43	1.00	0.68	1.15
Asset Turnover Ratio (%)	0.81	1.22	1.43	1.67	1.40
Current Ratio (X)	1.08	1.08	1.18	1.29	1.34
Quick Ratio (X)	0.69	0.82	0.91	1.11	1.05
Inventory Turnover Ratio (X)	3.51	6.02	9.22	10.37	5.81
Interest Coverage Ratio (X)	2.71	2.83	2.69	4.06	3.09
Interest Coverage Ratio (Post Tax) (X)	1.93	2.15	1.91	2.84	2.25
Enterprise Value (Cr.)	125.12	123.00	87.45	67.32	60.89
EV / Net Operating Revenue (X)	1.10	0.78	0.54	0.41	0.49
EV / EBITDA (X)	9.77	8.83	8.27	5.82	5.95
MarketCap / Net Operating Revenue (X)	0.58	0.44	0.35	0.30	0.28
Price / BV (X)	1.52	1.80	1.71	1.66	1.41
Price / Net Operating Revenue (X)	0.58	0.44	0.35	0.30	0.28
EarningsYield	0.06	0.07	0.06	0.10	0.11

After reviewing the key financial ratios for Godavari Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 7.37 (Mar 24) to 5.82, marking a decrease of 1.55.
For Diluted EPS (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 7.37 (Mar 24) to 5.82, marking a decrease of 1.55.
For Cash EPS (Rs.), as of Mar 25, the value is 9.07. This value is within the healthy range. It has decreased from 10.02 (Mar 24) to 9.07, marking a decrease of 0.95.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.56. It has increased from 51.74 (Mar 24) to 57.56, marking an increase of 5.82.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.56. It has increased from 51.74 (Mar 24) to 57.56, marking an increase of 5.82.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 150.52. It has decreased from 208.10 (Mar 24) to 150.52, marking a decrease of 57.58.
For PBDIT / Share (Rs.), as of Mar 25, the value is 17.00. This value is within the healthy range. It has decreased from 18.49 (Mar 24) to 17.00, marking a decrease of 1.49.
For PBIT / Share (Rs.), as of Mar 25, the value is 13.75. This value is within the healthy range. It has decreased from 15.84 (Mar 24) to 13.75, marking a decrease of 2.09.
For PBT / Share (Rs.), as of Mar 25, the value is 7.47. This value is within the healthy range. It has decreased from 9.19 (Mar 24) to 7.47, marking a decrease of 1.72.
For Net Profit / Share (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 7.37 (Mar 24) to 5.82, marking a decrease of 1.55.
For PBDIT Margin (%), as of Mar 25, the value is 11.29. This value is within the healthy range. It has increased from 8.88 (Mar 24) to 11.29, marking an increase of 2.41.
For PBIT Margin (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 10. It has increased from 7.61 (Mar 24) to 9.13, marking an increase of 1.52.
For PBT Margin (%), as of Mar 25, the value is 4.96. This value is below the healthy minimum of 10. It has increased from 4.41 (Mar 24) to 4.96, marking an increase of 0.55.
For Net Profit Margin (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 5. It has increased from 3.54 (Mar 24) to 3.86, marking an increase of 0.32.
For Return on Networth / Equity (%), as of Mar 25, the value is 10.10. This value is below the healthy minimum of 15. It has decreased from 14.24 (Mar 24) to 10.10, marking a decrease of 4.14.
For Return on Capital Employeed (%), as of Mar 25, the value is 14.79. This value is within the healthy range. It has decreased from 22.60 (Mar 24) to 14.79, marking a decrease of 7.81.
For Return On Assets (%), as of Mar 25, the value is 3.06. This value is below the healthy minimum of 5. It has decreased from 4.11 (Mar 24) to 3.06, marking a decrease of 1.05.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.28 (Mar 24) to 0.55, marking an increase of 0.27.
For Total Debt / Equity (X), as of Mar 25, the value is 1.42. This value exceeds the healthy maximum of 1. It has decreased from 1.43 (Mar 24) to 1.42, marking a decrease of 0.01.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has decreased from 1.22 (Mar 24) to 0.81, marking a decrease of 0.41.
For Current Ratio (X), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 1.08.
For Quick Ratio (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.82 (Mar 24) to 0.69, marking a decrease of 0.13.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.51. This value is below the healthy minimum of 4. It has decreased from 6.02 (Mar 24) to 3.51, marking a decrease of 2.51.
For Interest Coverage Ratio (X), as of Mar 25, the value is 2.71. This value is below the healthy minimum of 3. It has decreased from 2.83 (Mar 24) to 2.71, marking a decrease of 0.12.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.93. This value is below the healthy minimum of 3. It has decreased from 2.15 (Mar 24) to 1.93, marking a decrease of 0.22.
For Enterprise Value (Cr.), as of Mar 25, the value is 125.12. It has increased from 123.00 (Mar 24) to 125.12, marking an increase of 2.12.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.10. This value is within the healthy range. It has increased from 0.78 (Mar 24) to 1.10, marking an increase of 0.32.
For EV / EBITDA (X), as of Mar 25, the value is 9.77. This value is within the healthy range. It has increased from 8.83 (Mar 24) to 9.77, marking an increase of 0.94.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has increased from 0.44 (Mar 24) to 0.58, marking an increase of 0.14.
For Price / BV (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has decreased from 1.80 (Mar 24) to 1.52, marking a decrease of 0.28.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has increased from 0.44 (Mar 24) to 0.58, marking an increase of 0.14.
For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.06, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Godavari Drugs Ltd as of November 11, 2025 is: 79.71

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 11, 2025, Godavari Drugs Ltd is Overvalued by 1.23% compared to the current share price 80.70

Intrinsic Value of Godavari Drugs Ltd as of November 11, 2025 is: 74.68

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 11, 2025, Godavari Drugs Ltd is Overvalued by 7.46% compared to the current share price 80.70

Last 5 Year EPS CAGR: -6.32%

*Investments are subject to market risks

Strength and Weakness

Unable to fetch valid data for stock valuation.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Godavari Drugs Ltd:
1. Net Profit Margin: 3.86%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 14.79% (Industry Average ROCE: 16.11%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 10.1% (Industry Average ROE: 14.47%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 1.93
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.69
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 16 (Industry average Stock P/E: 46.92)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 1.42
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

FAQ: Stock data is invalid or not in the correct format.